🦴
Musculoskeletal · Clinical Topics
Osteoporosis
Osteoporosis is a systemic skeletal disorder characterised by low bone mass and micro-architectural deterioration, leading to increased bone fragility and fracture risk. It is often asymptomatic until a fragility fracture occurs. Management involves risk assessment (FRAX), DXA scanning, and pharmacological treatment usually with bisphosphonates.
📌 Learning Objectives
- Define osteoporosis and osteopenia based on DXA T-scores.
- Identify key risk factors for primary and secondary osteoporosis.
- Explain the role of osteoclasts and osteoblasts in bone remodelling and how this balance is altered in osteoporosis.
- Outline the diagnostic approach to osteoporosis, including the use of FRAX and DXA scanning.
- Describe the main pharmacological treatments for osteoporosis, including their mechanisms of action and important patient counselling points.
- Recognise the clinical presentations of fragility fractures and their associated morbidity and mortality.
📋 Overview
Osteoporosis is defined by the WHO as a Bone Mineral Density (BMD) T-score of -2.5 or lower on a Dual-energy X-ray Absorptiometry (DXA) scan. It is a major public health concern in the UK, particularly among postmenopausal women due to the loss of the protective effect of oestrogen. Fragility fractures—those resulting from a fall from standing height or less—are the hallmark clinical event, commonly occurring in the hip, vertebrae, and wrist (Colles' fracture). Risk factors include age, female sex, smoking, alcohol, glucocorticoid use, and secondary causes like hyperthyroidism or malabsorption. Management involves assessing the 10-year fracture risk using the FRAX or QFracture tools. Treatment is indicated for those with high risk or confirmed osteoporosis on DXA. First-line therapy is oral bisphosphonates (Alendronic acid), which inhibit osteoclast activity. Adequate Vitamin D and Calcium intake are essential adjuncts. Follow-up typically involves repeat DXA every 3-5 years to monitor treatment efficacy.
🔬 Basic Science
Bone is a dynamic tissue undergoing constant remodelling by osteoclasts (resorption) and osteoblasts (formation). In osteoporosis, this balance is disturbed, leading to a net loss of bone. Postmenopausal osteoporosis is driven by oestrogen deficiency, which increases the expression of RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL binds to RANK on osteoclast precursors, promoting their differentiation and survival. This results in excessive bone resorption. Age-related (senile) osteoporosis involves a decline in osteoblast function and decreased Vitamin D production. The micro-architecture of trabecular bone becomes thinned and disconnected, significantly reducing the bone's ability to withstand mechanical stress despite a normal mineral-to-collagen ratio (unlike osteomalacia).
🏥 Clinical Relevance
Osteoporosis is 'silent' until a fracture occurs. Vertebral fractures may present as loss of height, progressive kyphosis ('dowager's hump'), or acute back pain. Hip fractures are associated with significant morbidity and a 20-30% mortality rate within one year. Clinical risk factors (CRFs) used in FRAX include: previous fracture, parental hip fracture, smoking, alcohol (>3 units/day), glucocorticoids (≥7.5mg prednisolone for >3 months), and Rheumatoid Arthritis. Secondary causes include Coeliac disease (malabsorption), hyperthyroidism, primary hyperparathyroidism, and hypogonadism (e.g., premature menopause).
🧪 Investigations
- Risk Assessment: FRAX tool (can be done without DXA to determine if DXA is needed).
- Imaging: DXA scan is the gold standard (L-spine and Hip). T-score compares BMD to a young healthy adult; Z-score compares BMD to age-matched controls.
- Bloods (to exclude secondary causes): FBC, U&E, LFTs (alkaline phosphatase), Bone profile (Calcium, Phosphate), Vitamin D, Thyroid function, Coeliac serology.
- Spinal X-rays: If vertebral fracture is suspected.
- Imaging: DXA scan is the gold standard (L-spine and Hip). T-score compares BMD to a young healthy adult; Z-score compares BMD to age-matched controls.
- Bloods (to exclude secondary causes): FBC, U&E, LFTs (alkaline phosphatase), Bone profile (Calcium, Phosphate), Vitamin D, Thyroid function, Coeliac serology.
- Spinal X-rays: If vertebral fracture is suspected.
💊 Management
Lifestyle: Weight-bearing exercise, smoking cessation, and moderate alcohol intake. Ensure Vitamin D (800 IU) and Calcium (1000mg) sufficiency. Medical: First-line is oral Bisphosphonates: Alendronic acid (70mg weekly) or Risedronate (35mg weekly). Patients must stay upright and fast for 30 minutes after taking these to prevent oesophagitis. Second-line/Specialist: IV Zoledronic acid (yearly), Denosumab (SC injection every 6 months), or HRT in younger postmenopausal women. Raloxifene (SERM) is an option. Teriparatide (anabolic) is reserved for very high risk with multiple fractures.
Revision Resources – expand the sections below for high-yield notes, exam pearls, key facts and further reading.
MLA High-Yield Notes & Quick Revision ⌄
FRAX categorises patients into Low (advice), Medium (DXA), or High (Treat). Bisphosphonates carry a small risk of atypical femoral fractures and osteonecrosis of the jaw (ONJ)—advise dental checkups.
Musculoskeletal pain (e.g., back pain from vertebral fractures)
Falls and immobility in older adults
Postmenopausal health
Chronic disease management
Nutritional deficiencies
Drug-induced conditions (e.g., glucocorticoid-induced osteoporosis)
- Osteoporosis is low bone mass and micro-architectural deterioration, increasing fracture risk.
- Defined by DXA T-score ≤ -2.5; osteopenia is -1.0 to -2.5.
- Key risk factors include age, female sex, postmenopause, glucocorticoids, and secondary causes.
- Bone remodelling imbalance: increased osteoclast activity (resorption) over osteoblast activity (formation).
- FRAX tool assesses 10-year fracture risk; DXA scan is gold standard for diagnosis.
- Bisphosphonates (e.g., Alendronic acid) are first-line treatment, inhibiting osteoclasts.
Exam Pearls ⌄
⭐ High Yield
Osteoporosis is defined by a DXA T-score ≤ -2.5; osteopenia is between -1.0 and -2.5.
FRAX is the primary UK tool for assessing 10-year fracture risk, guiding the need for DXA or treatment.
Bisphosphonates (e.g., Alendronic acid) are first-line, inhibiting osteoclast activity; patients must remain upright and fast for 30 mins after taking.
Oestrogen deficiency in postmenopausal women increases RANKL, leading to increased osteoclast activity and bone resorption.
Common fragility fractures occur in the hip, vertebrae, and wrist (Colles' fracture).
Secondary causes like Coeliac disease, hyperthyroidism, and glucocorticoid use must be considered and excluded.
Hip fractures carry significant morbidity and a 20-30% mortality rate within one year.
Adequate Vitamin D and Calcium intake are essential adjuncts to pharmacological treatment.
💡 Clinical Pearl
Coeliac Disease: Malabsorption can lead to nutrient deficiencies (e.g., calcium, vitamin D) contributing to secondary osteoporosis.
Hyperkalaemia: While not directly related to osteoporosis, it's a common electrolyte imbalance often seen in patients with chronic conditions, which may include those with osteoporosis, requiring careful management.
Chronic Kidney Disease: Can lead to renal osteodystrophy, a complex bone disorder that includes features of osteoporosis, osteomalacia, and osteitis fibrosa cystica, due to altered calcium, phosphate, and vitamin D metabolism.
Hypertension: Common comorbidity in older patients; some antihypertensives can affect bone metabolism or fall risk, indirectly impacting osteoporosis management.
⚠️ Exam Tip — Common Mistakes
Confusing osteoporosis with osteomalacia (osteoporosis is reduced bone quantity, osteomalacia is defective mineralisation).
Underestimating the importance of lifestyle modifications (weight-bearing exercise, smoking cessation).
Failing to consider secondary causes of osteoporosis, especially in younger patients or those with unusual presentations.
Not counselling patients correctly on bisphosphonate administration (staying upright, fasting).
Over-relying on calcium and vitamin D supplementation without considering pharmacological treatment in high-risk individuals.
Missing the 'silent' nature of osteoporosis until a fracture occurs, leading to delayed diagnosis.
Key Facts ⌄
Defined by a T-score ≤ -2.5 on DXA scan.
Osteopenia is defined as a T-score between -1.0 and -2.5.
Hip, vertebral, and wrist fractures are most common.
FRAX score is the standard UK tool for 10-year fracture risk assessment.
Bisphosphonates (e.g., Alendronic acid) are the mainstay of treatment.
Lifestyle factors: Weight-bearing exercise, smoking cessation, and limiting alcohol.
Secondary causes (e.g., hyperparathyroidism, Coeliac) must be excluded.
Related Topics ⌄
References ⌄
- NICE CKS - Osteoporosis
- NOGG Guidelines (2022)
- BNF
Further Resources
Medical Portfolio & Career Development
Build a professional portfolio website for applications, audits, teaching, research and career progression.
CVtoWebsite.com →